Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;127(8):1264-1270.
doi: 10.1002/jso.27317.

Management of lateral pelvic lymph nodes in rectal cancer

Gloria Chang  1 , Wissam J Halabi  2 , Fadwa Ali  1
Affiliations
Review

Management of lateral pelvic lymph nodes in rectal cancer

Gloria Chang et al. J Surg Oncol. 2023 Jun.

Abstract

Lateral pelvic lymph node (LPLN) involvement occurs in 10%-25% of rectal cancer cases. Total mesorectal excision (TME) with routine LPLN dissection (LPLND) is predominantly applied in Japan whereas TME with neoadjuvant treatment are used in the West. LPLND is a morbid procedure and minimally invasive techniques may help reduce its morbidity. Selective lateral pelvic node dissection with TME following neoadjuvant treatment achieves acceptable disease-free and overall survival.

Keywords: lateral pelvic lymph nodes; pelvic lymphadenopathy; rectal adenocarcinoma; rectal cancer.

PubMed Disclaimer

References

REFERENCES

    1. Hojo K, Koyama Y, Moriya Y. Lymphatic spread and its prognostic value in patients with rectal cancer. Am J Surg. 1982;144(3):350-354. doi:10.1016/0002-9610(82)90018-6
    1. Morikawa E, Yasutomi M, Shindou K, et al. Distribution of metastatic lymph nodes in colorectal cancer by the modified clearing method. Dis Colon Rectum. 1994;37(3):219-223. doi:10.1007/bf02048158
    1. Ogura A, Konishi T, Cunningham C, et al. Neoadjuvant (chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3/4 rectal cancer. J Clin Oncol. 2019;37(1):33-43. doi:10.1200/JCO.18.00032
    1. MacFarlane JK, Ryall RDH, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341(8843):457-460. doi:10.1016/0140-6736(93)90207-W
    1. Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1-42. doi:10.1007/s10147-019-01485-z

LinkOut - more resources